Publications

Detailed Information

p53 Codon 72 and p21 Codon 31 Polymorphisms and Susceptibility to Cervical Adenocarcinoma in Korean Women

DC Field Value Language
dc.contributor.authorRoh, Ju-Won-
dc.contributor.authorKim, Bu Kyung-
dc.contributor.authorLee, Chae Hyeong-
dc.contributor.authorKim, Jongseung-
dc.contributor.authorKim, Jae Weon-
dc.contributor.authorSong, Yong-Sang-
dc.contributor.authorKang, Soon-Beom-
dc.contributor.authorPark, Sang-Yoon-
dc.contributor.authorPark, Noh-Hyun-
dc.contributor.authorChung, Hyun Hoon-
dc.date.accessioned2012-06-28T06:01:41Z-
dc.date.available2012-06-28T06:01:41Z-
dc.date.issued2010-
dc.identifier.citationONCOLOGY RESEARCH; Vol.18 9; 453-459ko_KR
dc.identifier.issn0965-0407-
dc.identifier.urihttps://hdl.handle.net/10371/77771-
dc.description.abstractThe aims of this study were to evaluate the genotype frequencies of p53 codon 72 and p21 codon 31 in cervical adenocarcinoma patients and controls, and the association between the specific genotype or genotype combination of these polymorphisms and the risk of cervical adenocarcinoma in Korean women. Genotyping was performed using DNA from cervical biopsy specimens collected from 53 patients with cervical adenocarcinoma, of whom 34 were HPV 16 or 18 positive, and from the cervical exfoliated cells from 286 control women, of whom 48 were positive for HPV 16 or 18. For the determination of p53 polymorphisms genomic DNA was examined by PCR amplification of the specific allele assay, and for the determination of p21 polymorphisms DNA was examined by the PCR-RFLP assay using BsmA1. We found significant differences in genotype frequencies of both genes between the two groups (p < 0.001). The p53 genotypes containing the Pro allele were significantly associated with cervical adenocarcinoma with an OR of 2.89 (95% Cl 1.54-5.42). Also, homozygous carriers of the p21 Ser allele showed a substantially increased risk of developing cervical adenocarcinoma (OR 2.07; 95% Cl 1.13-3.79) compared to genotypes containing the Are allele. In addition, the combination of the Pro allele containing genotypes of p53 and the Ser homozygous genotype of p21 posed a remarkably increased risk (OR 5.22; 95% Cl 2.24-12.16), although the interaction of the two genes could not be found. These significant differences were intensified in groups with high-risk HPV infection (types 16 or 18).ko_KR
dc.language.isoenko_KR
dc.publisherCOGNIZANT COMMUNICATION CORPko_KR
dc.subjectp21 codon 31ko_KR
dc.subjectCervical cancerko_KR
dc.subjectAdenocarcinomako_KR
dc.subjectPolymorphismko_KR
dc.subjectp53 codon 72ko_KR
dc.titlep53 Codon 72 and p21 Codon 31 Polymorphisms and Susceptibility to Cervical Adenocarcinoma in Korean Womenko_KR
dc.typeArticleko_KR
dc.contributor.AlternativeAuthor노주원-
dc.contributor.AlternativeAuthor김부경-
dc.contributor.AlternativeAuthor이채형-
dc.contributor.AlternativeAuthor김종승-
dc.contributor.AlternativeAuthor정현훈-
dc.contributor.AlternativeAuthor김재원-
dc.contributor.AlternativeAuthor박노현-
dc.contributor.AlternativeAuthor송용상-
dc.contributor.AlternativeAuthor박상윤-
dc.contributor.AlternativeAuthor강순범-
dc.identifier.doi10.3727/096504010X12671222663719-
dc.citation.journaltitleONCOLOGY RESEARCH-
dc.description.citedreferenceShin HR, 2008, INT J CANCER, V122, P393, DOI 10.1002/ijc.23015-
dc.description.citedreferenceSantos AM, 2006, EUR J CANCER, V42, P958, DOI 10.1016/j.ejca.2006.01.015-
dc.description.citedreferenceBhattacharya P, 2005, GYNECOL ONCOL, V99, P176, DOI 10.1016/j.ygyno.2005.06.007-
dc.description.citedreferenceLi GJ, 2005, CARCINOGENESIS, V26, P1596, DOI 10.1093/carcin/bgi105-
dc.description.citedreferenceRoh JW, 2004, GYNECOL ONCOL, V93, P499, DOI 10.1016/j.ygyno.2004.02.005-
dc.description.citedreferenceWu MT, 2004, CANCER LETT, V205, P61, DOI 10.1016/j.canlet.2003.11.026-
dc.description.citedreferenceKoushik A, 2004, CANCER EPIDEM BIOMAR, V13, P11-
dc.description.citedreferenceHelt AM, 2002, J VIROL, V76, P10559, DOI 10.1128/JVI.76.20.10559-10568.2002-
dc.description.citedreferencePowell BL, 2002, CARCINOGENESIS, V23, P311-
dc.description.citedreferenceLee EY, 2002, TOXICOL IND HEALTH, V18, P201, DOI 10.1191/0748233702th141oa-
dc.description.citedreferenceAndersson S, 2001, BRIT J CANCER, V85, P1153-
dc.description.citedreferenceKlug SJ, 2001, CANCER EPIDEM BIOMAR, V10, P1009-
dc.description.citedreferenceHildesheim A, 2001, BRIT J CANCER, V84, P1219, DOI 10.1054/bjoc.2001.1779-
dc.description.citedreferenceRoh JW, 2001, CANCER LETT, V165, P59-
dc.description.citedreferenceHarima Y, 2001, INT J MOL MED, V7, P261-
dc.description.citedreferenceKim JW, 2001, AM J OBSTET GYNECOL, V184, P55, DOI 10.1067/mob.2001.108329-
dc.description.citedreferenceYang YC, 2001, GYNECOL OBSTET INVES, V51, P197-
dc.description.citedreferenceShih CM, 2000, JPN J CANCER RES, V91, P9-
dc.description.citedreferenceTachezy R, 1999, HUM GENET, V105, P564-
dc.description.citedreferenceWalboomers JMM, 1999, J PATHOL, V189, P12-
dc.description.citedreferenceZehbe I, 1999, LANCET, V354, P218-
dc.description.citedreferenceKIM JW, 1999, J KOREAN CANC ASS, V31, P403-
dc.description.citedreferenceMinaguchi T, 1998, CANCER RES, V58, P4585-
dc.description.citedreferenceStorey A, 1998, NATURE, V393, P229-
dc.description.citedreferenceBirgander R, 1996, HUM HERED, V46, P148-
dc.description.citedreferenceZAKUT R, 1995, ONCOGENE, V11, P393-
dc.description.citedreferenceSUN Y, 1995, CANCER EPIDEM BIOMAR, V4, P261-
dc.description.citedreferenceCHEDID M, 1994, ONCOGENE, V9, P3021-
dc.description.citedreferenceELDEIRY WS, 1993, CELL, V75, P817-
dc.description.citedreferenceHOPKINS MP, 1991, OBSTET GYNECOL, V77, P912-
dc.description.citedreferenceSCHEFFNER M, 1990, CELL, V63, P1129-
dc.description.citedreferenceBRINTON LA, 1987, CANCER RES, V47, P1706-
dc.description.tc2-
Appears in Collections:
Files in This Item:
There are no files associated with this item.

Altmetrics

Item View & Download Count

  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Share